Patient and tumor characteristics of systematic and lobe-specific LND groups in propensity score-matched cohort
| Variables . | Systematic LND n = 83 . | Lobe-specific LND n = 83 . | P value . | SD . | |
|---|---|---|---|---|---|
| Clinical variables | Age, years | 67 (62–73) | 67 (60–73) | 0.76 | 0.073 |
| Sex, male/female | 60 (72.3%)/23 (27.7%) | 60 (72.3%)/23 (27.7%) | 1.00 | 0 | |
| Whole tumor size, cm | 3.0 (2.4–4.0) | 3.0 (2.3–3.8) | 0.73 | 0.037 | |
| Solid component size, cm | 2.8 (2.2–4.0) | 2.8 (2.1–3.8) | 0.79 | 0.0073 | |
| C/T ratio | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.40 | 0.065 | |
| SUVmax | 8.4 (5.9–13.5) | 8.9 (4.9–13.8) | 0.86 | 0.016 | |
| cT, T1/T2/T3 | 40 (48.2%)/29 (35.0%)/14 (16.8%) | 38 (45.8%)/31 (37.4%)/14 (16.8%) | 0.94 | 0.057 | |
| cN, N0/N1/N2 | 41 (49.4%)/31 (37.4%)/11 (13.2%) | 47 (56.6%)/25 (30.1%)/11 (13.3%) | 0.59 | 0.17 | |
| Side, right/left | 52 (62.7%)/31 (37.3%) | 45 (54.2%)/38 (45.8%) | 0.35 | 0.18 | |
| Lobe, upper/lower | 48 (57.8%)/35 (42.2%) | 49 (59.0%)/34 (41.0%) | 1.00 | 0.027 | |
| Pathological and Postoperative variables | Histology Adenocarcinoma Squamous cell carcinoma Others | 58 (69.9%) 15 (18.1%) 10 (12.0%) | 60 (72.3%) 13 (15.7%) 10 (12.0%) | 0.92 | 0.070 |
| Pathologic tumor size, cm | 3.0 (2.5–4.0) | 3.0 (2.2–4.0) | 0.59 | 0.031 | |
| Pathologic invasive size, cm | 3.0 (2.0–4.0) | 2.7 (2.0–3.5) | 0.73 | 0.024 | |
| Lymphatic invasion | 63 (75.9%) | 57 (68.7%) | 0.39 | 0.17 | |
| Vascular invasion | 66 (79.5%) | 64 (77.1%) | 0.85 | 0.064 | |
| Pleural invasion | 39 (47.0%) | 43 (51.8%) | 0.64 | 0.10 | |
| Number of dissected LNs | 20 (16–26) | 17 (13–25) | 0.026 | 0.28 | |
| Median number of dissected metastasis LNs | 3 (2–6) | 2 (1–4) | 0.014 | 0.33 | |
| Pathologic N status N1 N2 | 37 (44.6%) 46 (55.4%) | 49 (59.0%) 34 (41.0%) | 0.087 | 0.32 | |
| Detail of N2 status aN2 in lobe-specific LND field bN2 in systematic LND field | c43 (51.8%) c11 (13.2%) | 34 (41.0%) 0 (0%) | 0.21 0.0007 | 0.21 0.55 | |
| Adjuvant chemotherapy | 44 (53.0%) | 48 (57.8%) | 0.64 | 0.10 | |
| Recurrence | 40 (48.2%) | 45 (54.2%) | 0.60 | 0.13 | |
| Recurrence pattern Locoregional Distant Locoregional and Distant | 9 (22.5%) 20 (50.0%) 11 (27.5%) | 14 (31.1%) 18 (40.0%) 13 (28.9%) | 0.59 | 0.18 | |
| Lymph node relapse | 12 (14.5%) | 17 (20.5%) | 0.41 | 0.18 | |
| Variables . | Systematic LND n = 83 . | Lobe-specific LND n = 83 . | P value . | SD . | |
|---|---|---|---|---|---|
| Clinical variables | Age, years | 67 (62–73) | 67 (60–73) | 0.76 | 0.073 |
| Sex, male/female | 60 (72.3%)/23 (27.7%) | 60 (72.3%)/23 (27.7%) | 1.00 | 0 | |
| Whole tumor size, cm | 3.0 (2.4–4.0) | 3.0 (2.3–3.8) | 0.73 | 0.037 | |
| Solid component size, cm | 2.8 (2.2–4.0) | 2.8 (2.1–3.8) | 0.79 | 0.0073 | |
| C/T ratio | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.40 | 0.065 | |
| SUVmax | 8.4 (5.9–13.5) | 8.9 (4.9–13.8) | 0.86 | 0.016 | |
| cT, T1/T2/T3 | 40 (48.2%)/29 (35.0%)/14 (16.8%) | 38 (45.8%)/31 (37.4%)/14 (16.8%) | 0.94 | 0.057 | |
| cN, N0/N1/N2 | 41 (49.4%)/31 (37.4%)/11 (13.2%) | 47 (56.6%)/25 (30.1%)/11 (13.3%) | 0.59 | 0.17 | |
| Side, right/left | 52 (62.7%)/31 (37.3%) | 45 (54.2%)/38 (45.8%) | 0.35 | 0.18 | |
| Lobe, upper/lower | 48 (57.8%)/35 (42.2%) | 49 (59.0%)/34 (41.0%) | 1.00 | 0.027 | |
| Pathological and Postoperative variables | Histology Adenocarcinoma Squamous cell carcinoma Others | 58 (69.9%) 15 (18.1%) 10 (12.0%) | 60 (72.3%) 13 (15.7%) 10 (12.0%) | 0.92 | 0.070 |
| Pathologic tumor size, cm | 3.0 (2.5–4.0) | 3.0 (2.2–4.0) | 0.59 | 0.031 | |
| Pathologic invasive size, cm | 3.0 (2.0–4.0) | 2.7 (2.0–3.5) | 0.73 | 0.024 | |
| Lymphatic invasion | 63 (75.9%) | 57 (68.7%) | 0.39 | 0.17 | |
| Vascular invasion | 66 (79.5%) | 64 (77.1%) | 0.85 | 0.064 | |
| Pleural invasion | 39 (47.0%) | 43 (51.8%) | 0.64 | 0.10 | |
| Number of dissected LNs | 20 (16–26) | 17 (13–25) | 0.026 | 0.28 | |
| Median number of dissected metastasis LNs | 3 (2–6) | 2 (1–4) | 0.014 | 0.33 | |
| Pathologic N status N1 N2 | 37 (44.6%) 46 (55.4%) | 49 (59.0%) 34 (41.0%) | 0.087 | 0.32 | |
| Detail of N2 status aN2 in lobe-specific LND field bN2 in systematic LND field | c43 (51.8%) c11 (13.2%) | 34 (41.0%) 0 (0%) | 0.21 0.0007 | 0.21 0.55 | |
| Adjuvant chemotherapy | 44 (53.0%) | 48 (57.8%) | 0.64 | 0.10 | |
| Recurrence | 40 (48.2%) | 45 (54.2%) | 0.60 | 0.13 | |
| Recurrence pattern Locoregional Distant Locoregional and Distant | 9 (22.5%) 20 (50.0%) 11 (27.5%) | 14 (31.1%) 18 (40.0%) 13 (28.9%) | 0.59 | 0.18 | |
| Lymph node relapse | 12 (14.5%) | 17 (20.5%) | 0.41 | 0.18 | |
Values are median (interquartile range) or n (%). SD, standardized difference.
aN2 in lobe-specific LND field is defined as N2 lymph node that could be dissected by lobe-specific LND
bN2 in systematic LND field is defined as N2 lymph node that could not be dissected by lobe-specific LND but could be dissected by systematic LND
c8 patients had both N2 lymph node in lobe-specific LND and systematic LND fields
Patient and tumor characteristics of systematic and lobe-specific LND groups in propensity score-matched cohort
| Variables . | Systematic LND n = 83 . | Lobe-specific LND n = 83 . | P value . | SD . | |
|---|---|---|---|---|---|
| Clinical variables | Age, years | 67 (62–73) | 67 (60–73) | 0.76 | 0.073 |
| Sex, male/female | 60 (72.3%)/23 (27.7%) | 60 (72.3%)/23 (27.7%) | 1.00 | 0 | |
| Whole tumor size, cm | 3.0 (2.4–4.0) | 3.0 (2.3–3.8) | 0.73 | 0.037 | |
| Solid component size, cm | 2.8 (2.2–4.0) | 2.8 (2.1–3.8) | 0.79 | 0.0073 | |
| C/T ratio | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.40 | 0.065 | |
| SUVmax | 8.4 (5.9–13.5) | 8.9 (4.9–13.8) | 0.86 | 0.016 | |
| cT, T1/T2/T3 | 40 (48.2%)/29 (35.0%)/14 (16.8%) | 38 (45.8%)/31 (37.4%)/14 (16.8%) | 0.94 | 0.057 | |
| cN, N0/N1/N2 | 41 (49.4%)/31 (37.4%)/11 (13.2%) | 47 (56.6%)/25 (30.1%)/11 (13.3%) | 0.59 | 0.17 | |
| Side, right/left | 52 (62.7%)/31 (37.3%) | 45 (54.2%)/38 (45.8%) | 0.35 | 0.18 | |
| Lobe, upper/lower | 48 (57.8%)/35 (42.2%) | 49 (59.0%)/34 (41.0%) | 1.00 | 0.027 | |
| Pathological and Postoperative variables | Histology Adenocarcinoma Squamous cell carcinoma Others | 58 (69.9%) 15 (18.1%) 10 (12.0%) | 60 (72.3%) 13 (15.7%) 10 (12.0%) | 0.92 | 0.070 |
| Pathologic tumor size, cm | 3.0 (2.5–4.0) | 3.0 (2.2–4.0) | 0.59 | 0.031 | |
| Pathologic invasive size, cm | 3.0 (2.0–4.0) | 2.7 (2.0–3.5) | 0.73 | 0.024 | |
| Lymphatic invasion | 63 (75.9%) | 57 (68.7%) | 0.39 | 0.17 | |
| Vascular invasion | 66 (79.5%) | 64 (77.1%) | 0.85 | 0.064 | |
| Pleural invasion | 39 (47.0%) | 43 (51.8%) | 0.64 | 0.10 | |
| Number of dissected LNs | 20 (16–26) | 17 (13–25) | 0.026 | 0.28 | |
| Median number of dissected metastasis LNs | 3 (2–6) | 2 (1–4) | 0.014 | 0.33 | |
| Pathologic N status N1 N2 | 37 (44.6%) 46 (55.4%) | 49 (59.0%) 34 (41.0%) | 0.087 | 0.32 | |
| Detail of N2 status aN2 in lobe-specific LND field bN2 in systematic LND field | c43 (51.8%) c11 (13.2%) | 34 (41.0%) 0 (0%) | 0.21 0.0007 | 0.21 0.55 | |
| Adjuvant chemotherapy | 44 (53.0%) | 48 (57.8%) | 0.64 | 0.10 | |
| Recurrence | 40 (48.2%) | 45 (54.2%) | 0.60 | 0.13 | |
| Recurrence pattern Locoregional Distant Locoregional and Distant | 9 (22.5%) 20 (50.0%) 11 (27.5%) | 14 (31.1%) 18 (40.0%) 13 (28.9%) | 0.59 | 0.18 | |
| Lymph node relapse | 12 (14.5%) | 17 (20.5%) | 0.41 | 0.18 | |
| Variables . | Systematic LND n = 83 . | Lobe-specific LND n = 83 . | P value . | SD . | |
|---|---|---|---|---|---|
| Clinical variables | Age, years | 67 (62–73) | 67 (60–73) | 0.76 | 0.073 |
| Sex, male/female | 60 (72.3%)/23 (27.7%) | 60 (72.3%)/23 (27.7%) | 1.00 | 0 | |
| Whole tumor size, cm | 3.0 (2.4–4.0) | 3.0 (2.3–3.8) | 0.73 | 0.037 | |
| Solid component size, cm | 2.8 (2.2–4.0) | 2.8 (2.1–3.8) | 0.79 | 0.0073 | |
| C/T ratio | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 0.40 | 0.065 | |
| SUVmax | 8.4 (5.9–13.5) | 8.9 (4.9–13.8) | 0.86 | 0.016 | |
| cT, T1/T2/T3 | 40 (48.2%)/29 (35.0%)/14 (16.8%) | 38 (45.8%)/31 (37.4%)/14 (16.8%) | 0.94 | 0.057 | |
| cN, N0/N1/N2 | 41 (49.4%)/31 (37.4%)/11 (13.2%) | 47 (56.6%)/25 (30.1%)/11 (13.3%) | 0.59 | 0.17 | |
| Side, right/left | 52 (62.7%)/31 (37.3%) | 45 (54.2%)/38 (45.8%) | 0.35 | 0.18 | |
| Lobe, upper/lower | 48 (57.8%)/35 (42.2%) | 49 (59.0%)/34 (41.0%) | 1.00 | 0.027 | |
| Pathological and Postoperative variables | Histology Adenocarcinoma Squamous cell carcinoma Others | 58 (69.9%) 15 (18.1%) 10 (12.0%) | 60 (72.3%) 13 (15.7%) 10 (12.0%) | 0.92 | 0.070 |
| Pathologic tumor size, cm | 3.0 (2.5–4.0) | 3.0 (2.2–4.0) | 0.59 | 0.031 | |
| Pathologic invasive size, cm | 3.0 (2.0–4.0) | 2.7 (2.0–3.5) | 0.73 | 0.024 | |
| Lymphatic invasion | 63 (75.9%) | 57 (68.7%) | 0.39 | 0.17 | |
| Vascular invasion | 66 (79.5%) | 64 (77.1%) | 0.85 | 0.064 | |
| Pleural invasion | 39 (47.0%) | 43 (51.8%) | 0.64 | 0.10 | |
| Number of dissected LNs | 20 (16–26) | 17 (13–25) | 0.026 | 0.28 | |
| Median number of dissected metastasis LNs | 3 (2–6) | 2 (1–4) | 0.014 | 0.33 | |
| Pathologic N status N1 N2 | 37 (44.6%) 46 (55.4%) | 49 (59.0%) 34 (41.0%) | 0.087 | 0.32 | |
| Detail of N2 status aN2 in lobe-specific LND field bN2 in systematic LND field | c43 (51.8%) c11 (13.2%) | 34 (41.0%) 0 (0%) | 0.21 0.0007 | 0.21 0.55 | |
| Adjuvant chemotherapy | 44 (53.0%) | 48 (57.8%) | 0.64 | 0.10 | |
| Recurrence | 40 (48.2%) | 45 (54.2%) | 0.60 | 0.13 | |
| Recurrence pattern Locoregional Distant Locoregional and Distant | 9 (22.5%) 20 (50.0%) 11 (27.5%) | 14 (31.1%) 18 (40.0%) 13 (28.9%) | 0.59 | 0.18 | |
| Lymph node relapse | 12 (14.5%) | 17 (20.5%) | 0.41 | 0.18 | |
Values are median (interquartile range) or n (%). SD, standardized difference.
aN2 in lobe-specific LND field is defined as N2 lymph node that could be dissected by lobe-specific LND
bN2 in systematic LND field is defined as N2 lymph node that could not be dissected by lobe-specific LND but could be dissected by systematic LND
c8 patients had both N2 lymph node in lobe-specific LND and systematic LND fields
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
